Skip to main content
  • Saved

made a Post

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

Source :

https://jitc.bmj.com/content/8/1/e000621

Bispecific antibodies (bsAb) and chimeric antigen receptor (CAR) T cells allow for antibody guided recruitment of T cells against tumors. Both are successfully used for treatment of CD19 expressing leukemias, but may cause cytokine release syndrome (CRS) as a major dose-limiting side effect.